France: Competition Newsletter March 2018

Last Updated: 26 March 2018
Article by Emmanuelle van den Broucke and Alexia Delaunay

A concerted practice between two pharmaceutical groups aiming to reduce the use of a medicinal product for treatments not covered by its marketing authorization and increasing the use of another competing medicine is likely to constitute a restriction of competition 'by object'

The Roche group produces two medicinal products: Avastin which, according to its marketing authorization (MA), is prescribed for the treatment of tumorous pathologies, and Lucentis, which is intended for the treatment of eye diseases and whose commercialization is entrusted to the Novartis group through a license agreement. In practice, Avastin, whose price is lower than that of Lucentis, is also used without an MA for the treatment of eye diseases.

The Italian Competition Authority imposed two fines worth approx. €90 million each to Roche and Novartis for concluding an agreement that was contrary to Article 101 of the Treaty of the Functioning of the European Union (TFEU) which aimed to obtain an artificial differentiation between the Avastin and Lucentis medicines. The agreement would have consisted, in a context of scientific uncertainty, in regarding the security of Avastin's ophthalmic use. Following the rejection of the two pharmaceutical laboratories' appeals against this decision, the latter brought the matter before the highest Italian administrative jurisdiction that referred five preliminary questions to the Court of Justice of the European Union.

Two of these questions concern the possibility of considering that these two medicines belong to the same market while, according to the parties, Avastin was sold without an MA and under conditions that did not comply with the pharmaceutical regulations. The Court of Justice answered that one medicine used without an MA can belong to the same market as a medicine with an MA if the prescribing doctors consider them interchangeable, as long as the products are produced and sold legitimately. In this case, the Court considered that the state of uncertainty regarding the lawfulness of the repackaging and prescription conditions of Avastin for the treatment of ocular pathologies did not prevent the Italian authority from considering that it belonged to the same market as Lucentis.

The question was also raised as to whether the competition restrictions for which the companies were criticized could escape the application of Article 101 paragraph 1 of the TFUE since they were ancillary to the license agreement concluded between Roche and Norvatis and strictly necessary to its performance. The Court considers that such provisions concerned the behavior of third parties to this agreement (prescribing doctors) and therefore could not be considered ancillary to said agreement. The two laboratories indeed agreed to raise, in a context of scientific uncertainty, concerns regarding the security of a medicine used for treatments not covered by its MA in order to reduce competitive pressure on the medicine with this indication in its MA. In this regard, the Court considers that this represents a restriction of competition 'by object' and believes that the degree of harm of such practice makes the analysis of its effects superfluous.

Lastly, the Court excludes the benefit of individual exemption as the restriction in issue cannot be qualified as essential.

Following the recent conviction of Janssen Cilag in France in December 2017 for having constrained the development of a generic medicine by interventions with health authorities and through a smear campaign directed at doctors, laboratories are once again reminded that all approaches aimed at limiting the use of products by raising unjustified concerns among users on the risks they present are serious restrictions of competition.

The Competition Authority reminds that the conditions of membership to an interbranch organization whose access is an essential condition for the practice of the activity must be transparent and non-discriminatory

On February 21, 2018, the Competition Authority approved the commitments of the interbranch association of Martinique for meat, livestock and milk (AMIV) which were proposed following a complaint by the Madras agricultural cooperative (SICA Madras) and the association Producteurs Agricoles et de la Mer Associés (PRAMA) whose requests to join the AMIV were rejected without any reason.

In May 2017, SICA Madras and PRAMA lodged a claim on the merits with the Competition Authority, and provisional measures in July, to contest the membership conditions to the AMIV. The case handlers considered that the criteria, as well as the membership procedure to the interbranch organization, which is deemed crucial in order to benefit from European aid that is essential for the practice of the activity and opportunities further downstream, were indeed likely to raise competition concerns, as they were neither objective nor transparent, and were likely to be discriminatory. After having undertaken a market test and requested the improvement of the commitments initially proposed by the AMIV, the Competition Authority considered that the commitments taken by the latter were likely to respond to the competition concerns raised by the case handlers.

In substance, the AMIV proposed a series of firm commitments consisting, firstly, in modifying the membership procedure of the organization to frame it within deadlines, to hear the candidates in the membership procedure and to provide a reason in case of a refusal. Regarding the membership criteria themselves, the AMIV undertook, for more transparency, to enter all the criteria in the internal rules and to modify the appreciation of the criteria related to representativeness, actual activity and specialization to make their application objective. Lastly, as a conditional commitment, the AMIV created a new temporary status of "associate member" with a simplified access procedure compared to the status of full member (no obligation to participate in inter-profession works). This status of associate member makes it possible to benefit from European aid without having to meet the access conditions of the full status, which are deemed disproportionate to benefit simply from such aid.

This decision recalls the need to guarantee objective and transparent access conditions and membership procedure to organizations, trade unions and other professional associations. The fact that the membership to the organization was in the case at hand essential to the practice of the activity was a determining factor in the Authority's analysis.

Formalistic approach by the Court of Cassation of the franchisor's pre-contractual disclosure obligation

By its decree dated January 10, 2018, the French Supreme Court does not fail to surprise by adopting a formalistic approach of the franchisor's pre-contractual disclosure obligation. It seemed rather established by case law that the franchise agreement (or, more specifically, any agreement providing a person with a trade name, brand or sign, and requiring from the latter an exclusivity or near-exclusivity obligation to practice their activity), could be canceled for failure of the franchisor to its pre-contractual disclosure obligation, only if the franchisee managed to establish that the missing information of the pre-contractual disclosure document (that has to be handed in 20 days prior to the signature of the agreement) had vitiated the latter's consent. However, in the case at hand, the Supreme Court censored the Bordeaux Court of Appeal because it did not verify if the pre-contractual disclosure document contained the information required by the Commercial Code. The Court of Appeal indeed settled to note that it follows from the facts of the case that the franchisee knew the concept of the franchise and its functioning and that it declared in the franchise agreement that it had received all the necessary information. As such, it did not answer the franchisee that reproached the franchisor of the absence of information regarding the liquidation of companies formerly managed by it and by former franchisees, the absence of a test site, of an operational handbook, of reliable information on the state of the market and of a credible forecast regarding development opportunities and the activity's results. The Supreme Court therefore overturns the decision of the Court of Appeal and refers the matter before another Court. This tougher approach from the Supreme Court must be taken into account seriously by the franchisors due to the significant consequences that a lack of information can raise: the invalidity of the agreement and its potential contagion effect on the entire network

Dentons is the world's first polycentric global law firm. A top 20 firm on the Acritas 2015 Global Elite Brand Index, the Firm is committed to challenging the status quo in delivering consistent and uncompromising quality and value in new and inventive ways. Driven to provide clients a competitive edge, and connected to the communities where its clients want to do business, Dentons knows that understanding local cultures is crucial to successfully completing a deal, resolving a dispute or solving a business challenge. Now the world's largest law firm, Dentons' global team builds agile, tailored solutions to meet the local, national and global needs of private and public clients of any size in more than 125 locations serving 50-plus countries. www.dentons.com.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Events from this Firm
25 Oct 2018, Other, Munich, Germany

Please register via RSVP button by October 15, 2018. If you have any questions, please contact Marcel Schmidt.

30 Oct 2018, Other, Frankfurt, Germany

With the blockchain market maturing, we see an advancing diversification of token types and offerings.

30 Oct 2018, Other, London, UK

The third campaign in Dentons' TechTalk series explores the role of Blockchain in the modern business world.

 
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Topics
 
Related Articles
 
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions